Preoperative Drug Monitoring in Management of Patients with Hip Fracture on Treatment with Direct Oral Anticoagulants
Carlo Rostagno,Giulio Maria Mannarino,Alessandro Cartei,Gaia Rubbieri,Alice Ceccofiglio,Anna Maria Gori,Roberto Civinini,Rossella Marcucci
DOI: https://doi.org/10.2147/cia.s444902
IF: 3.829
2024-04-30
Clinical Interventions in Aging
Abstract:Carlo Rostagno, 1, 2 Giulio Maria Mannarino, 2 Alessandro Cartei, 2 Gaia Rubbieri, 2 Alice Ceccofiglio, 2 Anna Maria Gori, 1– 4 Roberto Civinini, 3 Rossella Marcucci 1– 4 1 Dipartimento Medicina sperimentale e clinica, Università di Firenze, Firenze, Italy; 2 Medicina Interna e Post-Chirurgica, AOU Careggi, Firenze, Italy; 3 Traumatologia e Ortopedia, AOU Careggi, Firenze, Italy; 4 Malattie aterotrombotiche, AOU Careggi, Firenze, Italy Correspondence: Carlo Rostagno, Asssociate Professor of Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence, 50134, Italy, Email Purpose: Aim of the present study was to evaluate whether monitoring direct oral anticoagulant (DOAC) levels may improve management of anticoagulated patients who need surgery for hip fracture. Patients and Methods: A total of 147 out of 2231 (7.7%) patients with hip fracture admitted to a tertiary teaching hospital were on DOACs (group A), whereas 206 patients matched for age, sex, and type of fracture not on anticoagulant or P2Y12 platelet inhibitors were considered as control group (group B). Patients on DOACs were divided into two subgroups: A1 in which intervention was scheduled in relation to the last drug intake according to current guidelines, and A2 included patients in whom time of surgery (TTS) was defined according to DOAC levels. Neuraxial anesthesia was considered with DOAC levels < 30 ng/mL, general anesthesia for levels in the range 30– 50 ng/mL. Results and conclusions: TTS was significantly lower in controls than in DOAC patients: surgery within 48 hours was performed in 80.6% of group B versus 51% in group A ( p < 0.0001). In A2, 41 patients underwent surgery within 48 hours (56%) in comparison to 32 A1 patients (45.1%; p =0.03). TTS and length of hospitalization were on average 1 day lower in patients with assay of DOAC levels. Finally, 35/39 (89%) patients with DOAC levels < 50 ng/mL had surgery within 48 hours (26 under neuraxial anesthesia, without any neurological complication, and 13 in general anesthesia). Conclusion: DOAC assay in patients with hip fracture may be useful for correct definition of time to surgery, particularly in patients who are candidates for neuraxial anesthesia. Two-thirds of patients with DOAC levels < 50 ng/mL at 48 hours from last drug intake underwent uneventful neuraxial anesthesia, saving at least 24 hours in comparison to guidelines. Keywords: fragility fractures, oral anticoagulants, DOAC assay, safety Hip fracture is a severe disabling condition in the elderly, leading to a 1-year over-mortality close to 20%, significantly higher than mortality reported in the age-matched general population. 1,2 Due to population aging, the global number of hip fractures is expected to increase four-fold between 1990 and 2050 with an estimated 5,000,000 cases per year. 3,4 Early surgery, within 24–48 hours from trauma, is associated with a lower rate of complications and decreased early and 1-year mortality. 5–8 Not less than 10% of patients with hip fracture are on chronic anticoagulant therapy at the moment of trauma. The increased risk of bleeding associated with anticoagulation is a well-known factor for surgical delay in patients with hip fracture, and several studies suggest that in patients treated with direct anticoagulants (DOACs) surgery is performed at least 12–24 hours later in comparison to non-anticoagulated patients. 9–13 Reversal therapy was not considered due the high costs related to idarucizumab administration for dabigatran antagonism. Moreover, andexanet is still not approved for reversal Xa inhibitors effects before surgery. Current guidelines suggest that, in patients at high risk of bleeding, surgery may be safely performed 48 hours after the last dose of anti-factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), while for dabigatran a longer delay should be considered in subjects with impairment of renal function. 14–16 When neuraxial anesthesia is considered, treatments should be delayed by a further 24 hours. In elderly patients drug interactions or age-related impairment of elimination mechanisms may modify pharmacokinetics of DOACs. Half-life may increase from 1.4- to 4.4-fold in comparison to times reported in the Summary of Product Characteristic. 17 The use of DOAC monitoring may help to schedule safe time to surgery and proper anesthesiologic procedure. According to literature serum levels below 50 ng/mL are associated with a low risk of bleeding, and neuraxial anesthesia may be considered safe for levels <30 ng/mL. 18–20 -Abstract Truncated-
geriatrics & gerontology,gerontology